- Treatment of Hepatitis B Virus Resistant to Lamivudine and Adefovir
-
Kim JW
- KMID: 1767700
- Korean J Gastroenterol.
- 2009 May;53(5):329-330.
- doi: 10.4166/kjg.2009.53.5.329
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Resistance to Adefovir in Patients with Chronic Hepatitis B
-
Ryu SH, Chung YH
- KMID: 938252
- Korean J Hepatol.
- 2006 Dec;12(4):484-492.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
-
Kim JH, Ahn SH, Ko SY, Choe WH, Kim KH, Kwon SY
- KMID: 2373120
- Clin Mol Hepatol.
- 2016 Jun;22(2):241-249.
- doi: 10.3350/cmh.2015.0053
BACKGROUND/AIMS: Before tenofovir (TDF) become available in South Korea, combination therapy with entecavir (ETV) and adefovir (ADV) was the most potent regimen for chronic hepatitis B (CHB) patients who fail... -
- CITED
-
- Close
- SHARE
-
- Close
- Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
-
Park JG, Park SY
- KMID: 2351024
- Clin Mol Hepatol.
- 2015 Sep;21(3):242-248.
- doi: 10.3350/cmh.2015.21.3.242
BACKGROUND/AIMS: We compared the efficacies of entecavir (ETV) plus tenofovir (TDF) and ETV plus adefovir (ADV) in chronic hepatitis B (CHB) patients with genotypic resistance to lamivudine (LAM) who showed... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
-
Ze E, Baek EK, Lee JJ, Chung HW, Ahn DG, Cho HJ, Kwon JC, Kim HJ, Lee H
- KMID: 2069763
- Clin Mol Hepatol.
- 2014 Sep;20(3):267-273.
- doi: 10.3350/cmh.2014.20.3.267
BACKGROUND/AIMS: Adefovir (ADV) and lamivudine (LAM) combination therapy (ADV+LAM) has been a useful option for patients with LAM-resistant (LAM-r) chronic hepatitis B (CHB). However, the long-term outcomes of LAM+ADV and... -
- CITED
-
- Close
- SHARE
-
- Close
- Current Antiviral Therapy for Chronic Hepatitis B
-
Lim YS, Suh DJ
- KMID: 2157673
- J Korean Med Sci.
- 2004 Aug;19(4):489-494.
- doi: 10.3346/jkms.2004.19.4.489
During the past decade, major breakthroughs have been achieved in treatment of chronic hepatitis B. Currently, three therapeutic agents are approved for chronic hepatitis B: interferon-alpha, lamivudine and adefovir dipivoxil.... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study
-
Cho EY, Yim HJ, Jung YK, Suh SJ, Seo YS, Kim JH, Kim HS, Lee SH, Ahn SH, Lee JI, Jeong SH, Kim JW, Lee JW, Kim IH, Kim HS, Park SJ, Lee JM, Hwang SG
- KMID: 2412164
- Gut Liver.
- 2017 Jan;11(1):129-135.
- doi: 10.5009/gnl15597
BACKGROUND/AIMS: Data are lacking regarding the management of chronic hepatitis B (CHB) with resistance to clevudine (CLV). This study evaluated the efficacy of different rescue therapies for CLV-resistant CHB. METHODS: Patients... -
- CITED
-
- Close
- SHARE
-
- Close
- High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B
-
Chae HB, Kim MJ, Seo EG, Choi YH, Lee HS, Han JH, Yoon SM, Park SM, Youn SJ
- KMID: 1372654
- Korean J Hepatol.
- 2012 Mar;18(1):75-83.
- doi: 10.3350/kjhep.2012.18.1.75
BACKGROUND/AIMS: Newly developed and potent antiviral agents suffer from the problem of drug resistance. Multidrug resistance is a major impediment in the treatment of patients with chronic hepatitis B (CHB).... -
- CITED
-
- Close
- SHARE
-
- Close
- Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
-
Kim JH, Ko SY, Choe WH, Kwon SY, Lee CH
- KMID: 1705205
- Clin Mol Hepatol.
- 2013 Sep;19(3):273-279.
- doi: 10.3350/cmh.2013.19.3.273
BACKGROUND/AIMS: Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB). The aim of this study was to... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B Viral Surface Mutations in Patients with Adefovir Resistant Chronic Hepatitis B with A181T/V Polymerase Mutations
-
Kim JH, Jung YK, Joo MK, Kim JH, Yim HJ, Park JJ, Kim JS, Bak YT, Yeon JE, Byun KS
- KMID: 1779257
- J Korean Med Sci.
- 2010 Feb;25(2):257-264.
- doi: 10.3346/jkms.2010.25.2.257
The hepatitis B virus (HBV) polymerase gene has overlapping reading frames with surface genes, which allows to alter the amino acid codon of the surface genes. In adefovir (ADV) treated... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure
-
Lee CI, Kwon SY, Kim JH, Choe WH, Lee CH, Yoon EL, Yeon JE, Byun KS, Kim YS, Kim JH
- KMID: 1774530
- Gut Liver.
- 2014 Jan;8(1):64-69.
BACKGROUND/AIMS: We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies. METHODS: Seventeen patients who failed to achieve... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Adefovir Dipivoxil in Patients with Decompensated Liver Cirrhosis with Lamivudine Resistance Compared to Patients with Compensated Liver Disease
-
Moon W, Choi MS, Moon YM, Paik SW, Lee JH, Koh KC, Yoo BC, Rhee JC, Shim SG
- KMID: 760590
- Korean J Hepatol.
- 2005 Jun;11(2):125-134.
BACKGROUND/AIMS: Adefovir dipivoxil is effective in patients with lamivudine-resistant hepatitis B virus (HBV). However, little is known about its role in Korean patients with decompensated liver cirrhosis. We retrospectively... -
- CITED
-
- Close
- SHARE
-
- Close
- Antiviral Efficacy of Lamivudine/Adefovir Combination Therapy in Chronic Hepatitis B Patients with Resistance to Lamivudine and Adefovir Consecutively
-
Suh HJ, Park MK, Lee HI, Gwak GY, Koh KC, Paik SW, Yoo BC, Lee JH
- KMID: 1767689
- Korean J Gastroenterol.
- 2009 May;53(5):305-310.
- doi: 10.4166/kjg.2009.53.5.305
BACKGROUND/AIMS: The aim of this study was to elucidate the antiviral efficacy of lamivudine (LMV)-adefovir (ADV) combination therapy in chronic hepatitis B patients who showed resistance to LMV and ADV... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Initial Virologic Response to Adefovir on the Development of Resistance to Adefovir in Lamivudine-resistant Chronic Hepatitis B
-
Kim IH, Kim SH, Kim HC, Shin KD, Kim SW, Lee SO, Lee ST, Kim DG
- KMID: 760736
- Korean J Hepatol.
- 2007 Sep;13(3):349-362.
- doi: 10.3350/kjhep.2007.13.3.349
BACKGROUND/AIMS: Adefovir dipivoxil (ADV) resistance in patients with lamivudine-resistant chronic hepatitis B is not well understood. This study examined the initial virologic response (IVR) to ADV, the rate of... -
- CITED
-
- Close
- SHARE
-
- Close
- Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients
-
Jung HW, Choi MS, Kim KH, Park SH, Yeon KK, Lee JH, Koh KC, Paik SW, Yoo BC
- KMID: 1776814
- Korean J Hepatol.
- 2009 Mar;15(1):52-58.
- doi: 10.3350/kjhep.2009.15.1.52
BACKGROUNDS/AIMS: It has been shown that adefovir dipivoxil is an effective antiviral agent in the treatment of chronic hepatitis B (CHB), not only in wild-type hepatitis B virus (HBV) infection,... -
- CITED
-
- Close
- SHARE
-
- Close
- Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus
-
Woo HY, Choi JY, Yoon SK, Suh DJ, Paik SW, Han KH, Um SH, Kim BI, Lee HJ, Cho M, Lee CK, Kim DJ, Hwang JS
- KMID: 1788566
- Clin Mol Hepatol.
- 2014 Jun;20(2):168-176.
- doi: 10.3350/cmh.2014.20.2.168
BACKGROUND/AIMS: Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV). The aim of this study was to determine the long-term clinical outcomes after... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
-
Lee HW, Park JY, Kim BK, Kim MY, Lee JI, Kim YS, Yoon KT, Han KH, Ahn SH
- KMID: 2373148
- Clin Mol Hepatol.
- 2016 Dec;22(4):443-449.
- doi: 10.3350/cmh.2016.0037
BACKGROUND/AIMS: It remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Add on Lamivudine to Adefovir Monotherapy for the Treatment of Lamivudine-resistant Chronic Hepatitis B Patients
-
Cho YJ, Cheong JY, Lee MH, Jeon SJ, Lee YC, Lim SG, Kang CJ, Cho SW
- KMID: 1775862
- Korean J Gastroenterol.
- 2010 Aug;56(2):83-89.
- doi: 10.4166/kjg.2010.56.2.83
BACKGROUND/AIMS: Add on adefovir (ADV) to ongoing lamivudine (LAM) has been recommended as a standard therapy for the treatment of LAM resistance. In the past, switch to ADV monotherapy was... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients
-
Cho JH, Cheong JY, Kang JK, Park JS, Lee MH, Lim NK, Hong SP, Kim SO, Yoo WD, Cho SW
- KMID: 1073330
- Korean J Hepatol.
- 2008 Mar;14(1):58-66.
- doi: 10.3350/kjhep.2008.14.1.58
BACKGROUND/AIMS: Adefovir dipivoxil (adefovir) effectively inhibits both wild-type and lamivudine-resistant hepatitis B virus (HBV) replication. The development of adefovir resistance is both delayed and infrequent compared with lamivudine resistance.... -
- CITED
-
- Close
- SHARE
-
- Close
- The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection
-
Moon JH, Cho M, Yoon KT, Bae JH, Heo J, Kim GH, Kang DH, Song GA
- KMID: 1073302
- Korean J Hepatol.
- 2008 Dec;14(4):503-512.
- doi: 10.3350/kjhep.2008.14.4.503
BACKGROUND/AIMS: Adefovir dipivoxil (ADV) is a nucleotide analogue that inhibits wild-type hepatitis B virus (HBV) and lamivudine (LMV)-resistant HBV mutants. The aim of this study was to elucidate the... -
- CITED
-
- Close
- SHARE
-
- Close
